Between 1996 and 1999, HIV patients treated with highly active antiretroviral therapy (HAART) as part of a clinical trial showed greater viral suppression than those patients who received the same treatment in a routine hospital setting, according to researchers at the University of North Carolina School of Medicine, demonstrating that just taking part in a clinical trial was enough to have a positive effect on health outcomes. The documentation of a so-called “trial effect,” which is assumed to be the result of increased care and follow-up as well as changes in the patients’ behavior, could impact how researchers design clinical trial and analyze the resulting data.

“Trial effect is notoriously difficult to test,” lead author Prema Menezes said in a press release. “This is the first study to clearly demonstrate a trial effect in HIV clinical trials, and this has important implications moving forward.”

The researchers found...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?